© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
October 23, 2020
While sickle cell disease is not prevalent in the general population, the significant cost associated with the condition warrants action from payers and formulary decision makers to improve patient access and align cost with their budgetary goals.
In her presentation, Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, discussed the upcoming pipeline of specialty drug approvals and their potential impact on the market.
In the current pipeline of specialty medications seeking approval, a majority of development lies within orphan drugs and cancer medications, said Aimee Tharaldson, PharmD, of Express Scripts.
The pressure on state budgets exerted by new approvals of costly therapeutics has led many states to implement legislation aimed at regulating drug prices, but the success of these efforts is not uniform across the nation.
October 22, 2020
Americans not covered by Medicaid should be aware of 2 key factors: the use of copay accumulators in commercial health plans and management of emerging high-cost specialty prescription drugs.
A collaborative effort between the health system and health plan pharmacists, as well as care managers and prescribers is key to improving clinical, quality outcomes in value-based payment models.
October 21, 2020
Pharmacists have an important role to play in the success of value-based payment models, according to panelists who discussed their health plan’s value initiatives at the Academy of Managed Care Pharmacy Nexus 2020 meeting.
For pharmacy practices to effectively manage specialty drugs, an extensive staff of pharmacists with clinical and managed care expertise is needed, as well as a collaborative effort between all those involved in the care team.
In a panel discussion at the Academy of Managed Care Pharmacy Nexus 2020 meeting, experts discussed driving factors of and barriers to the use of real-world evidence by payers in oncology decision-making.
In assessing a post–coronavirus disease 2019 (COVID-19) world, several aspects may impact managed care pharmacy practices long-term, including self-administration of therapies and issues in pharmacy reimbursement spotlighted by the pandemic.